This study evaluated patient-initiated single-dose antibiotic prophylaxis and continuous long-term low-dose daily antibiotic use for the prevention of recurrent urinary tract infections (UTI) in 68 postmenopausal women. The women were randomized to take a low-dose antibiotic each night (continuous group, n = 37) or a single-dose antibiotic each time they experienced conditions predisposing to UTI (intermittent group, n = 31). During the 12-month study, 1.4 and 1.9 UTIs/patient developed in the continuous and the intermittent groups, respectively, which was significantly lower than the incidence of UTIs in the previous 12 months in these patients (4.7 and 5.1 UTIs/patient, respectively). The incidence of gastro intestinal adverse events was significantly lower in the intermittent group compared with the continuous group (9.1% versus 30.0%). In conclusion, patient-initiated single-dose intermittent antibiotic prophylaxis was as effective as low-dose daily antibiotic prophylaxis in the treatment of recurrent UTIs in postmenopausal women and was associated with fewer gastrointestinal adverse events.
Introduction
Recurrent urinary tract infection (UTI) is defined as two or more episodes of urinary tract infection in 6 months or three or more episodes during a 12-month period. 1 According to a large Dutch study, 2 there is a high rate of recurrent UTIs in postmenopausal women (16.4%), rising to 19.1% in postmenopausal women with diabetes. The incidence in postmenopausal women is probably due to at least two factors: first, many postmenopausal women have urological issues such as incontinence, cystocele and postvoiding residual urine as a consequence of childbirth and loss of pelvic tone; and, secondly, low oestrogen levels YH Zhong, Y Fang, JZ Zhou et al. Antibiotic prophylaxis for recurrent UTI cause a marked change in the susceptibility of the uroepithelium and vagina to pathogens. 3, 4 Both these factors are hard to rectify. Oestrogen replacement therapy could significantly reduce UTI episodes in some patients but at the cost of an increased risk of developing tumours and cardiovascular disease. 5, 6 A long-term, low-dose daily antibiotic regimen is often administered as prophylaxis to prevent UTI recurrence and has been found to be effective in some randomized control trials. 7 -9 Treatment is, however, often complicated by adverse events, particularly gastrointestinal symptoms, vaginal candidiasis and skin rash. 10, 11 In young women, UTIs are often associated with sexual activity. One randomized control trial compared postcoital versus continuous daily ciprofloxacin and found no significant difference in rates of UTI, suggesting postcoital prophylaxis is as effective as daily prophylaxis. 12 Predisposing factors for UTIs in postmenopausal women are generally different from those in young women; for instance, long-distance walking or travelling can raise intra-abdominal pressure and temporarily aggravate incontinence, cystocele or postvoiding residual urine. 13 The present study assessed the effectiveness and safety of prophylactic single-dose antibiotics, taken after exposure to certain conditions associated with UTI recurrence, compared with continuous lowdose daily antibiotic prophylaxis in postmenopausal women.
Patients and methods

STUDY POPULATION
Consecutive postmenopausal outpatients with recurrent UTIs who were willing to participate in the study were recruited and prospectively followed in the Department of Nephrology, Zhongshan Hospital, Shanghai, China, between August 2005 and September 2009. Each patient underwent a urine test, renal ultrasound and a gynaecological evaluation.
Eligible patients were postmenopausal women with recurrent UTIs and no pyuria or bacteriuria in the 2 weeks prior to enrolment in the study. Recurrent UTI was defined as three or more episodes of UTI within a 12-month period. Exclusion criteria included: polycystic kidney disease; urinary obstruction; in-dwelling urinary catheterization; cystostomy; moderate to severe hydronephrosis (renal pelvic separation of ≥ 15 mm by ultrasound or Xray examination); moderate-to-severe uroschesis (persistence of a residual urine volume > 50 -100 ml); prolapsed uterus and/or bladder; surgical operation in the previous month; genitourinary tuberculosis; chronic renal insufficiency; chronic liver disease; transplantation; presence of a malignant tumour; receiving immunosuppressive therapy; chronic diarrhoea and/or constipation; local or systemic application of hormone replacement therapy; disturbed consciousness; no awareness of disease status; long-term bedridden or life-dependent. Patients with a vaginal fungal infection or severe senile vaginitis on gynaecological examination were enrolled in the study only after these conditions were in remission.
Written and verbal informed consent for participation in the study was obtained from all patients and the study protocol was approved by the Ethics Committee for Human Research of Zhongshan Hospital, Fudan University.
PROPHYLAXIS REGIMEN AND STUDY PROCEDURES
Patients were randomly assigned, using a random number table, into either the continuous low-dose daily antibiotic YH Zhong, Y Fang, JZ Zhou et al.
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prophylaxis group (continuous group) or the intermittent patient-initiated single-dose antibiotic prophylaxis group (intermittent group). Patients in the continuous group took a single-dose of antibiotic every night for 12 months. For each antibiotic, one specific dose was used for all patients: 1 50 mg/day furantoin; 200/40 mg/day sulphamethazine-trimethoprim (SMZ-TMP); 200 mg/day norfloxacin; 125 mg/day ciprofloxacin; 500 mg/day amoxicillin; 250 mg/day cefaclor; or 250 mg/day cefuroxime. The antibiotic prescribed depended on previous antimicrobial susceptibility testing and was changed every 2 -4 weeks. Patients in the intermittent group were asked to take a single-dose antibiotic every time they were exposed to conditions predisposing to UTIsuch as, sexual intercourse, travelling, working or walking for a long time, emiction holdback, diarrhoea or constipation -that were determined according to the patient's experience. The antibiotics prescribed for the intermittent group were selected from the same list as for the continuous group, with one antibiotic chosen per patient and used when needed throughout the 12-month study period. Selection of antibiotics was done on a case by case basis, based on the patient's past use of a particular antibiotic and antimicrobial susceptibility testing.
EFFICACY AND SAFETY ASSESSMENTS
Patients had regular urine examinations every 2 − 4 weeks for the 12 months of the study. Blood, liver and renal function tests were performed at months 2, 6 and 12 of the study, or when the patients had symptoms of a UTI. Conditions predisposing to antibiotic use in the intermittent group, the occurrence of a UTI and adverse events were recorded for all patients. Gynaecological examination was used to diagnose mycotic vaginitis when patients experienced symptoms such as vulvar pruritus, burning pain, increasing leucorrhoea, or flocculant secretion. The occurrence of a UTI was suspected with symptoms of micturition frequency or urgency, urodynia, with/without lumbar soreness and pain, chills and fever, tenderness at the lumbocostal point and pubic arch or percussion pain in the renal region. Microscopic pyuria in a urine test was requisite for diagnosis of a UTI, with or without > 10 5 cfu/ml bacteria on urine culture. 14
STATISTICAL ANALYSES
All statistical analyses were performed with the SPSS ® statistical package, version 11.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Continuous variables with normal distributions are presented as mean ± SD. A two-sample t-test was used to analyse continuous variables. Categorical variables were compared using a χ 2 -test or Fisher's exact test as appropriate. A value of P < 0.05 was considered to be statistically significant.
Power calculation to determine the minimum sample size required to demonstrate a statistical difference with α = 0.05 was carried out using PASS (Power Analysis and Sample Size) software, version 11.0.7 (NCSS Statistical & Power Analysis Software, Kaysville, UT, USA) for Windows ® . Sample size calculations suggested that approximately 300 patients/group were required. For financial and practical reasons, however, the study was designed based on a much smaller sample size of approximately 40 patients/group, hence is statistically underpowered.
Results
STUDY POPULATION
A total of 83 postmenopausal women with recurrent UTIs were enrolled in the study (41 in the intermittent group, 42 in the YH Zhong, Y Fang, JZ Zhou et al. Antibiotic prophylaxis for recurrent UTI continuous group). In the intermittent group, 10 patients dropped out of the study: five were lost to follow up, three had doubts about the effectiveness of the prophylaxis after recurrence of UTI and withdrew from the study, one was withdrawn due to skin rash and one was withdrawn due to gastrointestinal symptoms. In the continuous group, five patients dropped out: three were withdrawn because of gastrointestinal symptoms, one was lost to follow up and one patient was worried about long-term antibiotic use and withdrew. Thus, 68 patients completed the study (31 in the intermittent group, 37 in the continuous group). There were no significant differences between the patients in the two groups with respect to their baseline characteristics or risk factors for UTIs. Ten patients in the intermittent group and 12 in the continuous group had risk factors for UTIs, with several risk factors usually appearing together in one patient (Table 1) .
PREDISPOSING FACTORS AND ANTIBIOTIC USE
The intermittent group was exposed to a condition predisposing to UTI occurrence on 1436 occasions during the 12-month study period, with one patient often exposed to two or more conditions simultaneously. The predisposing factors for UTI used by patients in the intermittent group to determine when to begin prophylactic single-dose antibiotic use are shown in Table 2 . Working or walking for > 2 h was the most common predisposing factor.
Antibiotic use in the two groups is shown in ( Table 3 ). There were no significant differences in the percentage use of each individual antibiotic between the two groups. Each patient in the intermittent group used antibiotics a mean ± SD of 40.7 ± 16.2 times during the 12-month study period. study was compared with that in the year of the study for both groups. Recurrent UTI in the intermittent group was reduced from 159 to 59 episodes/year, which was a significant reduction from 5.1 to 1.9 episodes/patient per year (P < 0.001). In the continuous group, incidences of recurrent UTI were reduced from 175 episodes/year to 52 episodes/year, a significant reduction from 4.7 to 1.4 episodes/patient year (P < 0.001). The difference between the two groups was not statistically significant, however the proportion of patients experiencing 0 or 1 episode/year in the continuous group was significantly higher than in the intermittent group (59.4% versus 35.5%; P < 0.05; Table 4 ).
CLINICAL EFFICACY
All occurrences of UTI in both groups were treated successfully with routine antibiotic therapy for 2 − 4 weeks and prophylaxis was carried on after remission, except for the three patients from the intermittent group who dropped out over their doubts about the effectiveness of the prophylaxis strategy.
ADVERSE EVENTS
The incidence of any adverse event in the intermittent group was significantly lower than that in the continuous group (63.6% versus 92.5%, P < 0.05). Gastrointestinal events in the continuous group were significantly higher than in the intermittent group (P < 0.05; Table 5 ). The relative risk for gastrointestinal events was 4.0 (95% confidence intervals 1.017, 15.730; P = 0.045, Fisher's exact test), favouring the continuous group. In nearly all patients who reported abdominal pain, it was resolved after receiving vitamin B 6 , or a gastric mucosa protective agent (H 2 -receptor antagonist or proton pump inhibitor) and continued antibiotic prophylaxis. Patients with 
Discussion
There is abundant evidence in the literature that recurrent UTIs can largely be prevented by long-term low-dose antibiotic prophylaxis. 15 The aim of such treatment is to maintain an antibiotic barrier in the bladder urine to prevent the multiplication of bacteria, which are known to ascend the female urethra at regular intervals. 16 A study on the natural history of recurrent UTIs, however, demonstrated that the number of recurrences experienced per woman varies substantially, ranging from 0.3 to 7.6 episodes/year, and infectious episodes were strikingly clustered at certain times. 17 Thus, continuous prophylaxis may result in unnecessary antibiotic use in women who have infrequent recurrences or clustered recurrences. Previous studies have shown that postcoital prophylaxis was as effective as daily prophylaxis in preventing UTIs, 18 and a single dose of 500 mg ciprofloxacin orally before urodynamic study (UDS) dramatically decreased the rate of UTIs after UDS from 14% to 1%. 19 These studies support the hypothesis that antibiotic prophylaxis could be administered intermittently before or after exposure to conditions predisposing to UTIs. Due to patient self-knowledge of UTI symptoms, some studies have shown that a positive outcome can be achieved with patients taking the initiative in recurrent UTI treatment. 20 -22 In these studies, the patient self-diagnosed and self-treated recurrent UTIs, which decreased unnecessary antimicrobial use and improved patient convenience.
The present study evaluated the efficacy and safety of patient-initiated UTI prophylaxis. The predisposing factors for UTI episodes differ from one patient to another; for instance, travelling, shopping or housework could result in UTIs in some patients, while sexual intercourse, emiction holdback or diarrhoea might be the main cause of UTIs in others. Thus, sufficient selfknowledge of previous UTIs is critical to identifying the factors that predispose them to UTI reoccurrence, leading to better prophylactic efficacy and lower antibiotic use.
For young women, sexual intercourse, diaphragm and/or spermicide exposure have been identified as important risk factors associated with UTI. 23, 24 In postmenopausal women, several physical factors contribute to a year on year increase in the incidence of bacteriuria, with occurrences in 10% -15% of women aged 65 -70 years and 15% -20% of women aged > 80 years. 25 -27 During the current 12-month study, the efficacy of antibiotic prophylaxis for recurrent UTIs was high in both the intermittent and continuous groups. The rate of UTI recurrence was significantly reduced in both groups compared with the rate in the year prior to prophylaxis. In a previous study, the number of UTI episodes per patient per year were reduced in general, by about 95% during antimicrobial prophylaxis compared with the period before prophylaxis. 15 Many patients in the present study had diabetes mellitus, hydronephrosis, uroschesis and stress incontinence, so UTIs would be likely to occur even without exposure to other predisposing factors. This may be the reason why the proportion of patients with ≤ 1 UTI episode in the continuous group was significantly higher than in the intermittent group.
Prophylactic antibioic regimens for recurrent UTIs include daily, weekly or monthly prophylaxis, postcoital prophylaxis and acute self treatment. One study showed that weekly prophylaxis was better than monthly prophylaxis; 10 however, to date, no study has compared daily and weekly prophylaxis. The frequency of antibiotic use in the intermittent • Received for publication 15 May 2011 • Accepted subject to revision 23 June 2011
• Revised accepted 6 October 2011 Copyright © 2011 Field House Publishing LLP group was 40.7 ± 16.2 times/patient year, which is nearly once a week, providing evidence that weekly prophylaxis may be as effective as daily prophylaxis.
Antibiotics use during the 12-month study period was dramatically less in the intermittent group than in the continuous group and was associated with lower levels of gastrointestinal adverse events. Diarrhoea and constipation were probably related to intestinal flora disturbance as a consequence of long-term antibiotic administration and symptoms were relieved after the application of bifidobacteria or active lactobacillus preparations.
Several antibiotics were used to allow for the different tolerance to individual antibiotics in the general population. For example, some patients may develop leucopenia after receiving SMZ-TMP, others may show gastrointestinal symptoms, such as abdominal pain and nausea, after taking nitrofurantoin, while some may present with a rash when taking ciprofloxacin. These adverse events make patients less inclined to continue with long-term prophylaxis. No particular antibiotic has shown significantly superior prophylactic efficacy to other antibiotics in previous studies. 28 -30 Because patients could self administer antibiotics when they experienced a UTI it was not possible to carry out urine cultures before treatment. Thus, the present study provided no data on whether long-term bacteriostasis could induce resistance to antibiotics. The fact that symptoms of UTIs were relieved and urine tests returned to normal as a result of 2 − 4 weeks of antibiotic treatment suggests a non-problematic level of antibiotic resistance. This is similar to previous studies, where no increased emergence of resistance was observed. 12, 31 There were limitations to the present study. The study only followed patients for 12 months and included a relatively small sample. Power calculation determined that approximately 300 patients/group were needed. Due practical and financial reasons, however, the study used a much smaller sample; < 40 patients/group were included in the final analysis. Studies including larger patient numbers may help clarify the prophylactic effectiveness and safety profile of intermittent antibiotic prophylaxis.
In conclusion, patient-initiated intermittent antibiotic use against specific predisposing factors showed similar prophylactic effectiveness, but fewer gastrointestinal adverse events, than a continuous bacteriostasis strategy and could be used as a prophylactic regimen for recurrent UTIs in postmenopausal women.
